Strategies to Improve Pain and Enjoy Life
CompletedNot applicableNCT03743402
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
In the Strategies to Improve Pain and Enjoy Life (STRIPE) study, the effectiveness of a multicomponent intervention will be tested, compared with usual care, on opioid dose and pain outcomes among patients on high dose (≥ 40 mg morphine equivalent dose) long-term opioid therapy in a randomized controlled trial. This intervention will have 4 components: a) telephone-delivered evidence-based pain self-management training, b) web-based video of successfully tapered patients with motivational interviewing debriefing, c) a voluntary, self-paced opioid taper, and d) opioid and non-opioid prescribing guidance for the patient's primary care provider.
Study details
- Official title
- Randomized Trial of Telephonic Pain Self-management to Promote Opioid Tapering
- Conditions
- Interventions
- Behavioral: Pain self-management training
- Behavioral: video education, motivational interviewing
- Behavioral: voluntary self-paced opioid taper
- Behavioral: prescribing guidance for primary care provider
- Other: usual care
- Sponsor
- University of Washington
- Collaborators
- Kaiser Permanente; National Institute on Drug Abuse (NIDA)
- Start date
- 2019-04-04
- Primary completion
- 2022-01-27
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * age 18-80 years * receiving care at a Kaiser Washington primary care clinic; * Chronic Non-Cancer Pain, defined as patient-reported pain on more than half the days in the past 6 months; * currently on higher-dose long-term opioid therapy, defined as \>90 days' supply in the past 180 days with a mean daily dose of 40 mg MED or greater in the past 90 days, as first identified via Kaiser's pharmacy dispensing data and subsequently validated by patient self-report during screening for the trial * consent to participate in the study arm to which they are randomly assigned * able to read, speak, and write English adequate for outcome measures * enrollment in Kaiser for at least 6 months prior and no plans to disenroll over the next year. Exclusion Criteria: * receiving treatment for cancer * enrollment in palliative or hospice care * use in past year of parenteral, transdermal, or transmucosal opioids * residing in nursing home or assisted living * using any implanted device for pain control * psychotic symptoms, psychiatric hospitalization or suicide attempts in the past year * current suicidal ideation with plan or intent * dementia diagnosis in Electronic Health Record * Patients on buprenorphine for any reason, or methadone or naltrexone for treatment of Opioid Use Disorder
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03743402